Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG2001 in KRAS mutated advanced solid tumors
NCT06237413Phase 2Recruiting
- Sponsor
- Zelgen
- Start
- Aug 2023
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ZG2001 in solid tumor (2 arms), sponsored by Zelgen. Primary endpoints: Dose Limiting Toxicity at 21 days and Treatment-Emergent Adverse Events at 24 months. Started Aug 2023; status: recruiting.
02
Drugs
ZG2001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06237413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06237413.